Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Efficacy of anti-ICOS agonist monoclonal antibodies in preclinical tumor models provides a rationale for clinical development as cancer immunotherapeutics

Bibliographic Details
Main Authors: Harvey, Christopher, Elpek, Kutlu, Duong, Ellen, Simpson, Tyler, Shu, ChengYi J, Shallberg, Lindsey, Wallace, Matthew, Sathyanarayanan, Sriram, Mabry, Robert, Briskin, Michael, Michaelson, Jennifer, Gajewski, Thomas F
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645516/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645516/

Similar Items